We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.32 | 0.65% | 49.33 | 49.00 | 49.44 | 49.45 | 48.98 | 49.25 | 1,187,869 | 21:50:39 |
From May 2019 to May 2024
By Inti Landauro
PARIS--The U.S. Food and Drug Administration has granted a priority review to evaluate the request to market Praluent, a new drug intended to treat hypercholesterolemia and developed by pharmaceutical labs Sanofi (SAN.FR) and Regeneron (REGN), the two firms said Monday.
The goal of the priority review is to get a decision on the application to get a biologics license which gives permission to introduce the drug into interstate commerce, within six months, or on July 24, the two firms said in a statement Monday.
Earlier this month, the European Medicines Agency accepted for review a request for market authorization of the drug, also known as alirocumab, the two companies said.
-Write to Inti Landauro at inti.landauro@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
